- Home
- PAMT vs ACIU Comparison
PAMT vs ACIU Comparison
Compare PAMT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- ACIU
- Stock Information
- Founded
- PAMT 1980
- ACIU 2003
- Country
- PAMT United States
- ACIU Switzerland
- Employees
- PAMT N/A
- ACIU N/A
- Industry
- PAMT Trucking Freight/Courier Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PAMT Industrials
- ACIU Health Care
- Exchange
- PAMT Nasdaq
- ACIU Nasdaq
- Market Cap
- PAMT 293.5M
- ACIU 247.4M
- IPO Year
- PAMT 1985
- ACIU 2016
- Fundamental
- Price
- PAMT $14.18
- ACIU $1.48
- Analyst Decision
- PAMT Hold
- ACIU Strong Buy
- Analyst Count
- PAMT 1
- ACIU 2
- Target Price
- PAMT $16.50
- ACIU $12.00
- AVG Volume (30 Days)
- PAMT 41.1K
- ACIU 194.4K
- Earning Date
- PAMT 04-29-2025
- ACIU 05-12-2025
- Dividend Yield
- PAMT N/A
- ACIU N/A
- EPS Growth
- PAMT N/A
- ACIU N/A
- EPS
- PAMT N/A
- ACIU N/A
- Revenue
- PAMT $714,646,000.00
- ACIU $30,136,397.00
- Revenue This Year
- PAMT $0.61
- ACIU N/A
- Revenue Next Year
- PAMT $10.29
- ACIU $676.94
- P/E Ratio
- PAMT N/A
- ACIU N/A
- Revenue Growth
- PAMT N/A
- ACIU 84.51
- 52 Week Low
- PAMT $11.01
- ACIU $1.43
- 52 Week High
- PAMT $23.70
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- PAMT N/A
- ACIU 24.24
- Support Level
- PAMT N/A
- ACIU $1.48
- Resistance Level
- PAMT N/A
- ACIU $1.62
- Average True Range (ATR)
- PAMT 0.00
- ACIU 0.12
- MACD
- PAMT 0.00
- ACIU -0.00
- Stochastic Oscillator
- PAMT 0.00
- ACIU 9.43
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.